MedTrace Logo

Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).

NCT02834975 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that tumor cell killing by cytotoxic chemotherapy exposes the immune system to high levels of tumor antigens.The combination of Paclitaxel/Carboplatin and Pembrolizumab may result in deeper and more durable responses compared with standard chemotherapy alone.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab on Day 1 of each cycle.

DRUG

Paclitaxel

* NACT: Paclitaxel on Day 1 of each cycle; * ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol.

DRUG

Carboplatin

Carboplatin IV on Day 1 of each cycle.

Sponsors & Collaborators

Principal Investigators

  • Marilyn Huang, MD, MS · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-22
Primary Completion
2022-09-01
Completion
2022-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02834975 on ClinicalTrials.gov